Read by QxMD icon Read

Secondary prevention MI

Kazuyuki Shimada
Stroke is known to frequently recur in patients with a history of cerebrovascular disease, and the control of hypertension is extremely important for the treatment of those patients. The robust relationship between the recurrent cerebrovascular disease and blood pressure control has been demonstrated in large-scale clinical studies. The antihypertensive drug therapy significantly reduces the recurrence rate of all types of cerebrovascular disease, incidences of myocardial infarction and all vascular events...
September 2016: Journal of Hypertension
Rafel Ramos, Xavier Albert, Joan Sala, Maria Garcia-Gil, Roberto Elosua, Jaume Marrugat, Anna Ponjoan, María Grau, Manel Morales, Antoni Rubió, Pedro Ortuño, Lia Alves-Cabratosa, Ruth Martí-Lluch
BACKGROUND: Diagnosis of unrecognized myocardial infarction (UMI) remains an open question in epidemiological and clinical studies, inhibiting effective secondary prevention of myocardial infarction. We aimed to determine the prevalence and incidence of Q-wave UMI in asymptomatic individuals aged 35 to 74years, and to ascertain the positive predictive value (PPV) of asymptomatic Q-wave to diagnose UMI. METHODS: Two population-based cross-sectional studies were conducted, in 2000 (with 10-year follow-up) and in 2005...
October 5, 2016: International Journal of Cardiology
Michael G Silverman, Brian A Ference, Kyungah Im, Stephen D Wiviott, Robert P Giugliano, Scott M Grundy, Eugene Braunwald, Marc S Sabatine
IMPORTANCE: The comparative clinical benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains uncertain. OBJECTIVE: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and nonstatin therapies. DATA SOURCES AND STUDY SELECTION: The MEDLINE and EMBASE databases were searched (1966-July 2016). The key inclusion criteria were that the study was a randomized clinical trial and the reported clinical outcomes included myocardial infarction (MI)...
September 27, 2016: JAMA: the Journal of the American Medical Association
Alfi Yasmina, Anthonius de Boer, Vera H M Deneer, Patrick C Souverein, Olaf H Klungel
AIMS: To assess antiplatelet use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet non-persistence. METHODS: This study was conducted in 4,690 patients from the Utrecht Cardiovascular Pharmacogenetics cohort with first MI between 1986-2010, who were followed for a maximum of 10 years. Medication use and event diagnosis were obtained from the Dutch PHARMO Record Linkage System. Antiplatelet users were classified as persistent users (gap between prescriptions ≤ 90 days), non-persistent users (>90 days gap and no refills), and restarters (a new prescription after a > 90 days gap)...
September 23, 2016: British Journal of Clinical Pharmacology
Jae Hong Park, Ju-Hee Seo, Young-Seoub Hong, Yu-Mi Kim, Je-Wook Kang, Jae-Ho Yoo, Hee Won Chueh, Jung Hyun Lee, Min Jung Kwak, Jeongseon Kim, Hae Dong Woo, Dong Woo Kim, Young Rong Bang, Byeong Moo Choe
BACKGROUND: Because the developing brain of a child is vulnerable to environmental toxins, even very low concentration of neurotoxin can affect children's neurodevelopment. Lead is a neurotoxic heavy metal which has the harmful effect on the striatal-frontal circuit of brain. This area of the brain is known to be closely related to attention deficit hyperactivity disorder (ADHD) pathophysiology. The primary objective of the present study was to investigate whether elevated blood lead concentration is a risk factor for ADHD...
September 22, 2016: BMC Pediatrics
Kazuyuki Shimada
Stroke is known to frequently recur in patients with a history of cerebrovascular disease, and the control of hypertension is extremely important for the treatment of those patients. The robust relationship between the recurrent cerebrovascular disease and blood pressure control has been demonstrated in large-scale clinical studies. The antihypertensive drug therapy significantly reduces the recurrence rate of all types of cerebrovascular disease, incidences of myocardial infarction and all vascular events...
September 2016: Journal of Hypertension
Jérémie Abtan, Deepak L Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Yasuo Ikeda, David Wu, Mary E Hanson, Hakima Hannachi, Puneet K Singhal, Philippe Gabriel Steg, Gregory Ducrocq
BACKGROUND: Although the rate of in-hospital ischemic events after myocardial infarction (MI) has dramatically decreased, long-term residual risk may remain substantial. However, most of the information on current residual risk is derived from highly selected randomized trials. HYPOTHESIS: In patients with previous MI and no prior ischemic stroke/transient ischemic attack (TIA), residual ischemic risk increases over time. METHODS: Using the international Reduction of Atherothrombosis for Continued Health (REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events globally and by geography...
September 2, 2016: Clinical Cardiology
Zuzana Motovska, Ota Hlinomaz, Roman Miklik, Milan Hromadka, Ivo Varvarovsky, Jaroslav Dusek, Jiri Knot, Jiri Jarkovsky, Petr Kala, Richard Rokyta, Frantisek Tousek, Petra Kramarikova, Bohumil Majtan, Stanislav Simek, Marian Branny, Jan Mrozek, Pavel Cervinka, Jiri Ostransky, Petr Widimsky
BACKGROUND: No randomized "head-to-head" comparison of the efficacy and safety of ticagrelor vs. prasugrel has been published in the seven years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. METHODS: This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction (AMI) treated with primary or immediate percutaneous coronary intervention (PCI)...
August 30, 2016: Circulation
Catherine Grodensky, Carol Golin, Megha A Parikh, Rebecca Ochtera, Carlye Kincaid, Jennifer Groves, Laura Widman, Chirayath Suchindran, Camille McGirt, Kemi Amola, Steven Bradley-Bull
OBJECTIVE: Although past research has demonstrated a link between the quality of motivational interviewing (MI) counseling and client behavior change, this relationship has not been examined in the context of sexual risk behavior among people living with HIV/AIDS. We studied MI quality and unprotected anal/vaginal intercourse (UAVI) in the context of SafeTalk, an evidence-based secondary HIV prevention intervention. METHODS: We used a structured instrument (the MISC 2...
August 13, 2016: Patient Education and Counseling
Erru Yang, Michael Stokes, Saga Johansson, Carl Mellström, Elizabeth Magnuson, David J Cohen, Phillip Hunt
OBJECTIVES: Longitudinal data are limited regarding outcomes and costs beyond one year after acute myocardial infarction (MI) among elderly (≥65 years old) United States patients. This study examined long-term outcomes and healthcare costs among elderly MI survivors. METHODS: .Retrospective analysis of 2002-2009 Medicare healthcare claims (5% random sample). Patients were ≥65 years old and survived ≥1 year without recurrent MI after MI hospitalization. Mortality, incidence of hospitalizations for stroke, major bleeding, MI, a composite endpoint (death, MI or stroke), and non-pharmacy healthcare costs were determined...
August 26, 2016: Cardiovascular Therapeutics
Lee Nedkoff, Matthew Knuiman, Michael S T Hobbs, Joseph Hung, Sushma Mathur, John Beilby, Anna Reynolds, Tom G Briffa, Derrick Lopez, Frank M Sanfilippo
INTRODUCTION: Accurate monitoring of acute coronary heart disease (CHD) is essential for understanding the effects of primary and secondary prevention and for planning of healthcare services. The ability to reliably monitor acute CHD has been affected by new diagnostic tests for myocardial infarction (MI) and changing clinical classifications and management of CHD. Our study will develop new and reliable methods for monitoring population trends in incidence, outcomes and health service usage for acute CHD and chest pain...
August 24, 2016: BMJ Open
Jacob A Doll, Anne S Hellkamp, Abhinav Goyal, Nadia R Sutton, Eric D Peterson, Tracy Y Wang
Importance: Patients with dual Medicare-Medicaid eligibility have a higher burden of chronic disease conditions and increased health care utilization compared with patients with Medicare coverage alone, but the treatment patterns and outcomes of dual-eligible patients with myocardial infarction (MI) are unknown. Objective: To examine the association of dual-eligible status with clinical outcomes and adherence to medication regimens (hereinafter "medication adherence") among older adults after MI...
August 17, 2016: JAMA Cardiology
Trevor J Orchard, Jye-Yu C Backlund, Tina Costacou, Patricia Cleary, Maria Lopes-Virella, Andrew P Levy, John M Lachin
AIMS/HYPOTHESIS: Haptoglobin(Hp) 2-2 genotype has been shown to increase coronary artery disease (CAD) risk in numerous type 2 diabetes studies but in only one type 1 diabetes cohort. We assessed the association of Hp2-2 with incident CAD over 26years of follow-up in 1303 Caucasian participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. METHODS: DCCT randomized volunteers with type 1 diabetes to intensive versus conventional therapy within two cohorts: 'primary prevention' with 1-5years diabetes duration and 'secondary intervention' with 1-15years diabetes duration and early retinopathy, with or without albuminuria, but no advanced complications...
November 2016: Journal of Diabetes and its Complications
Sarah Zaman, Andrew J Taylor, Martin Stiles, Clara Chow, Pramesh Kovoor
The 'Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction' (PROTECT-ICD) trial is an Australian-led multicentre randomised controlled trial targeting prevention of sudden cardiac death in patients who have at least moderately reduced cardiac function following a myocardial infarct (MI). The primary objective of the trial is to assess whether electrophysiological study to guide prophylactic implantation of an implantable cardioverter-defibrillator (ICD) early following MI (first 40 days) will lead to a significant reduction in sudden cardiac death and non-fatal arrhythmia...
November 2016: Heart, Lung & Circulation
Sunil V Rao, Uwe Zeymer, Pamela S Douglas, Hussein Al-Khalidi, Jennifer A White, Jingyu Liu, Howard Levy, Victor Guetta, C Michael Gibson, Jean-Francois Tanguay, Paul Vermeersch, Jérôme Roncalli, Jaroslaw D Kasprzak, Timothy D Henry, Norbert Frey, Oscar Kracoff, Jay H Traverse, Derek P Chew, Jose Lopez-Sendon, Reinilde Heyrman, Mitchell W Krucoff
BACKGROUND: Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial infarctions in experimental models. OBJECTIVES: This study aimed to analyze whether BCM, compared with saline control, would result in less LV dilation and fewer adverse clinical events between baseline and 6 months. METHODS: In an international, randomized, double-blind, controlled trial, 303 subjects with large areas of infarction despite successful primary percutaneous coronary intervention (PCI) of ST-segment elevation myocardial infarction (STEMI) were randomized 2:1 to BCM or saline injected into the infarct-related artery 2 to 5 days after primary PCI...
August 16, 2016: Journal of the American College of Cardiology
A Varga, C M Tatar, A Mitre, C Podoleanu, I Tilea
OBJECTIVE: Atrial fibrillation is one of the most frequent complications of hypertension. Proper management of this condition with anticoagulation treatment requires data of the atrial fibrillation events rate in hypertensive population. Adequate standards of safety and optimal level of anticoagulation for preventing further cerebrovascular events is the target of this pilot center. DESIGN AND METHOD: Medical records from a family medicine database practice were evaluated...
September 2016: Journal of Hypertension
Nina Johnston, Johan Bodegard, Susanna Jerström, Johanna Åkesson, Hilja Brorsson, Joakim Alfredsson, Per A Albertsson, Jan-Erik Karlsson, Christoph Varenhorst
BACKGROUND: Patients with myocardial infarction (MI) seldom reach recommended targets for secondary prevention. This study evaluated a smartphone application ("app") aimed at improving treatment adherence and cardiovascular lifestyle in MI patients. DESIGN: Multicenter, randomized trial. METHODS: A total of 174 ticagrelor-treated MI patients were randomized to either an interactive patient support tool (active group) or a simplified tool (control group) in addition to usual post-MI care...
August 2016: American Heart Journal
Joo-Hyun Shin, Hyo-Jin Jeon, Jihye Park, Mi-Sook Chang
Human mesenchymal stem cells (hMSCs) have great therapeutic potential due to their high plasticity, immune privileged status and ease of preparation, as well as a lack of ethical barriers to their use. However, their ultimate usefulness is limited by cellular senescence occurring secondary to increased cellular levels of reactive oxygen species (ROS) during their propagation in culture. The underlying molecular mechanisms responsible for this process in hMSCs remain unclear. An antioxidant polyphenol epigallocatechin-3-gallate (EGCG) found in green tea, is known to activate nuclear factor-erythroid 2-related factor 2 (Nrf2), a master transcriptional regulator of antioxidant genes...
October 2016: International Journal of Molecular Medicine
Iraklis C Moschonas, Alexandros D Tselepis
Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial metabolic disease mainly characterized by hyperglycemia and insulin resistance. Abnormal platelet reactivity associated with an increased risk of cardiovascular disease (CVD) is also a feature characteristic of patients with T2DM. Dual antiplatelet therapy consisting of aspirin and an adenosine diphosphate platelet P2Y12 receptor antagonist, such as clopidogrel, represents the standard antithrombotic regimen for the secondary prevention of CVD risk in T2DM...
August 3, 2016: Journal of Cardiovascular Pharmacology and Therapeutics
Zaher Fanari, Amratash Malodiya, Sandra A Weiss, Sumaya Hammami, Paul Kolm, William S Weintraub
BACKGROUND: The potential benefit of long-term dual antiplatelet therapy (DAPT) for secondary prevention of atherothrombotic events is unclear. Data from different randomized controlled trials (RCT) using different agents in different subgroups showed inconsistent results. METHODS: We performed a systematic review and meta-analysis from RCTs that tested different prolonged durations of DAPT for secondary prevention. Long term DAPT arm was defined as those receiving DAPT for more than 12months...
July 20, 2016: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"